Sutro Biopharma, Inc.

NasdaqGM:STRO Aktierapport

Börsvärde: US$586.3m

Sutro Biopharma Tidigare resultatutveckling

Tidigare kriterier kontrolleras 0/6

Sutro Biopharma s intäkter har minskat med en genomsnittlig årlig takt på -21.8%, medan Biotechs -branschen såg intäkter på växande 29.1% årligen. Intäkterna har varit växande med en genomsnittlig takt på 17.3% per år.

Viktig information

-21.79%

Tillväxttakt i vinsten

-5.83%

Tillväxttakt för EPS

Biotechs Tillväxt i branschen17.04%
Intäkternas tillväxttakt17.31%
Avkastning på eget kapitaln/a
Nettomarginal-186.45%
Senaste uppdateringen av resultatet31 Dec 2025

Senaste uppdateringar av tidigare prestationer

Recent updates

Sutro Biopharma: Recycling Past Data Ahead Of The Readout, Sell

May 01

STRO: ADC Progress And Equity Offering Will Shape Balanced Future Outlook

Analysts have raised their price target for Sutro Biopharma by about $2, reflecting updated fair value estimates along with revised assumptions for the discount rate, revenue growth, profit margin and future P/E. What's in the News Sutro reported promising preclinical data for multiple next generation antibody drug conjugates (ADCs), including STRO-004, STRO-006 and STRO-227, at the American Association for Cancer Research Annual Meeting 2026.

STRO: Equity Offering And Lockup Structure Will Support Future Upside

Analysts now place Sutro Biopharma's price target at about $30.11, up from roughly $27.88. This reflects updated assumptions around fair value, discount rate, future revenue trends, profit margin, and a higher future P/E of about 199x.

STRO: Recent Equity Raises And Lockup Structure Will Support Future Upside

Analysts have revised their price target for Sutro Biopharma from $21.25 to $27.88, reflecting updated assumptions around discount rate, revenue growth, profit margin, and a higher future P/E in their models. What's in the News Sutro Biopharma filed a follow-on equity offering of up to US$100 million in common stock as an at-the-market program, providing flexibility to issue shares over time.

STRO: Equity Raise And Index Removal Will Set Up Future Upside Potential

Analysts have kept their $51.00 price target on Sutro Biopharma unchanged, as a slightly lower discount rate and a higher assumed future P/E multiple are seen as offsetting a softer revenue outlook and reduced profit margin expectations. What's in the News Sutro Biopharma completed a follow on equity offering of approximately US$110.0 million, issuing 7,868,383 common shares at US$13.98 per share with a US$0.8388 discount per share (Key Developments).

STRO: Reverse Split And Equity Raise Will Support Future Upside

Analysts have inched up their price target on Sutro Biopharma to $21.25 from $21, citing updated assumptions that include a slightly lower discount rate, modest changes to long term profit margin expectations, and a higher future P/E multiple. What's in the News Sutro Biopharma completed a follow on equity offering of common stock, raising about US$110.0m through the sale of 7,868,383 shares at US$13.98 per share, reflecting a US$0.8388 per share discount (Key Developments).

STRO: Reverse Split And ADC Pipeline Progress Will Support Future Upside Potential

Analysts have maintained their price target on Sutro Biopharma at US$51.00, making only minor adjustments to their models. Slightly softer assumptions for long-term revenue growth and profit margins are largely offset by a higher future P/E multiple.

Here's Why We're A Bit Worried About Sutro Biopharma's (NASDAQ:STRO) Cash Burn Situation

Feb 04
Here's Why We're A Bit Worried About Sutro Biopharma's (NASDAQ:STRO) Cash Burn Situation

STRO: Reverse Split And ADC Pipeline Progress Will Drive Future Upside

Analysts lifted their price target on Sutro Biopharma to US$51.00 per share, highlighting updated assumptions around fair value, discount rate, revenue growth expectations, profit margins, and a slightly lower future P/E as the key drivers of the change. What's in the News Sutro Biopharma regained compliance with Nasdaq’s continued listing standard for minimum share price under Rule 5450(a)(1) after its common stock maintained an average closing price of at least US$1.00 following a 1:10 reverse stock split effective December 3, 2025 (company announcement).

STRO: Reverse Split And ADC Pipeline Progress Will Support Future Upside

Analysts have trimmed their price target on Sutro Biopharma from US$22.29 to US$21.00, citing updated assumptions that include a slightly lower discount rate, a wider expected revenue decline of about 6.3 percentage points, a modestly higher profit margin, and a higher future P/E multiple. What's in the News Sutro Biopharma was removed from the Nasdaq Biotechnology Index, which can affect index fund ownership that tracks this benchmark (Index Constituent Drops).

Sutro Biopharma, Inc.'s (NASDAQ:STRO) Price Is Right But Growth Is Lacking After Shares Rocket 46%

Dec 31
Sutro Biopharma, Inc.'s (NASDAQ:STRO) Price Is Right But Growth Is Lacking After Shares Rocket 46%

STRO: Reverse Split And ADC Pipeline Focus Will Drive Future Upside

Narrative Update on Sutro Biopharma Analysts have reduced their price target on Sutro Biopharma from approximately $28.00 to about $22.30 per share. This reflects a lower assumed future price to earnings multiple, while expectations for revenue growth and profit margins remain largely unchanged.

STRO: Reverse Split And ADC Focus Will Drive Long-Term Upside

Analysts have raised their price target on Sutro Biopharma from 2.69 dollars to 28.00 dollars, citing expectations for improved long term profit margins despite softer revenue growth assumptions and a modestly higher discount rate. What's in the News Sutro Biopharma approved a 1 for 10 reverse stock split or significant stock dividend effective December 3, 2025, aimed at improving its share price profile for investors (company announcement).

ADC Pipeline Focus Will Advance Preclinical Drug Development

The downward revision in Sutro Biopharma’s price target reflects worsening net profit margin and deeper negative revenue growth forecasts, with fair value decreasing from $3.11 to $2.69. What's in the News Sutro Biopharma entered a collaboration with the FDA to co-develop reference materials and improve regulatory standards for ADC drug development, leveraging Sutro's XpressCF technology and FDA's analytical capabilities.

Here's Why We're A Bit Worried About Sutro Biopharma's (NASDAQ:STRO) Cash Burn Situation

Jul 01
Here's Why We're A Bit Worried About Sutro Biopharma's (NASDAQ:STRO) Cash Burn Situation

Benign Growth For Sutro Biopharma, Inc. (NASDAQ:STRO) Underpins Stock's 36% Plummet

Apr 18
Benign Growth For Sutro Biopharma, Inc. (NASDAQ:STRO) Underpins Stock's 36% Plummet
User avatar

ADC Pipeline Focus Will Advance Preclinical Drug Development

Strategic focus on preclinical programs and restructuring is set to drive future growth by enhancing drug development and revenue potential.

Sutro Biopharma, Inc. (NASDAQ:STRO) Not Doing Enough For Some Investors As Its Shares Slump 25%

Mar 04
Sutro Biopharma, Inc. (NASDAQ:STRO) Not Doing Enough For Some Investors As Its Shares Slump 25%

Sutro Biopharma: I Don't Buy That Their Pipeline Is Worthless

Jan 02

Why Investors Shouldn't Be Surprised By Sutro Biopharma, Inc.'s (NASDAQ:STRO) 26% Share Price Plunge

Nov 30
Why Investors Shouldn't Be Surprised By Sutro Biopharma, Inc.'s (NASDAQ:STRO) 26% Share Price Plunge

Revenues Working Against Sutro Biopharma, Inc.'s (NASDAQ:STRO) Share Price Following 25% Dive

Oct 11
Revenues Working Against Sutro Biopharma, Inc.'s (NASDAQ:STRO) Share Price Following 25% Dive

Sutro Biopharma's Competitive ADCs Position It For Future Growth In Oncology

Sep 23

There's No Escaping Sutro Biopharma, Inc.'s (NASDAQ:STRO) Muted Revenues Despite A 29% Share Price Rise

Aug 24
There's No Escaping Sutro Biopharma, Inc.'s (NASDAQ:STRO) Muted Revenues Despite A 29% Share Price Rise

Brokers Are Upgrading Their Views On Sutro Biopharma, Inc. (NASDAQ:STRO) With These New Forecasts

Aug 22
Brokers Are Upgrading Their Views On Sutro Biopharma, Inc. (NASDAQ:STRO) With These New Forecasts

Analysts Are Upgrading Sutro Biopharma, Inc. (NASDAQ:STRO) After Its Latest Results

Aug 16
Analysts Are Upgrading Sutro Biopharma, Inc. (NASDAQ:STRO) After Its Latest Results

The Market Doesn't Like What It Sees From Sutro Biopharma, Inc.'s (NASDAQ:STRO) Revenues Yet As Shares Tumble 28%

Jun 26
The Market Doesn't Like What It Sees From Sutro Biopharma, Inc.'s (NASDAQ:STRO) Revenues Yet As Shares Tumble 28%

We Think The Compensation For Sutro Biopharma, Inc.'s (NASDAQ:STRO) CEO Looks About Right

May 31
We Think The Compensation For Sutro Biopharma, Inc.'s (NASDAQ:STRO) CEO Looks About Right

Bearish: Analysts Just Cut Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue and EPS estimates

Apr 02
Bearish: Analysts Just Cut Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue and EPS estimates

The Market Doesn't Like What It Sees From Sutro Biopharma, Inc.'s (NASDAQ:STRO) Revenues Yet

Mar 28
The Market Doesn't Like What It Sees From Sutro Biopharma, Inc.'s (NASDAQ:STRO) Revenues Yet

Sutro Biopharma, Inc.'s (NASDAQ:STRO) Price Is Right But Growth Is Lacking After Shares Rocket 43%

Dec 19
Sutro Biopharma, Inc.'s (NASDAQ:STRO) Price Is Right But Growth Is Lacking After Shares Rocket 43%

Is Sutro Biopharma (NASDAQ:STRO) Using Debt In A Risky Way?

Aug 24
Is Sutro Biopharma (NASDAQ:STRO) Using Debt In A Risky Way?

Is Sutro Biopharma (NASDAQ:STRO) Using Too Much Debt?

Feb 10
Is Sutro Biopharma (NASDAQ:STRO) Using Too Much Debt?

An Intrinsic Calculation For Sutro Biopharma, Inc. (NASDAQ:STRO) Suggests It's 47% Undervalued

Jan 12
An Intrinsic Calculation For Sutro Biopharma, Inc. (NASDAQ:STRO) Suggests It's 47% Undervalued

Sutro Biopharma: Partnership Progress Warrants Exposure

Aug 16

Fördelning av intäkter och kostnader

Hur Sutro Biopharma tjänar och spenderar pengar. Baserat på senast rapporterade resultat, på rullande tolvmånadersbasis.

Resultat- och intäktshistorik

NasdaqGM:STRO Intäkter, kostnader och resultat (USD Millions )
DatumIntäkterIntäkterG+A KostnaderFoU-kostnader
31 Dec 25102-191410
30 Sep 25106-217410
30 Jun 25104-209470
31 Mar 2566-245490
31 Dec 2462-227480
30 Sep 24161-124560
30 Jun 24169-124570
31 Mar 24154-115600
31 Dec 23154-107630
30 Sep 2349-172600
30 Jun 2357-143600
31 Mar 2375-130600
31 Dec 2268-119600
30 Sep 2270-123610
30 Jun 2253-134630
31 Mar 2253-114600
31 Dec 2162-106560
30 Sep 2160-127480
30 Jun 2169-79410
31 Mar 2150-43390
31 Dec 2043-32370
30 Sep 204613380
30 Jun 2040-17360
31 Mar 2041-61340
31 Dec 1943-56330
30 Sep 1951-42320
30 Jun 1946-40290
31 Mar 1941-38250
31 Dec 1838-35220
30 Sep 1823-49180
30 Jun 1833-40180
31 Mar 1842-30170
31 Dec 1752-20160
31 Dec 16600150

Kvalitetsintäkter: STRO är för närvarande olönsam.

Växande vinstmarginal: STRO är för närvarande olönsam.

Fritt kassaflöde vs resultatanalys

Analys av tidigare vinsttillväxt

Resultatutveckling: STRO är olönsam och förlusterna har ökat under de senaste 5 åren i en takt av 21.8% per år.

Accelererande tillväxt: Det går inte att jämföra STRO s intäktstillväxt under det senaste året med dess 5-åriga genomsnitt eftersom det för närvarande är olönsamt

Resultat vs industri: STRO är olönsam, vilket gör det svårt att jämföra det senaste årets vinsttillväxt med Biotechs branschen ( 50.1% ).

Avkastning på eget kapital

Hög ROE: STRO s skulder överstiger dess tillgångar, så det är svårt att beräkna dess avkastning på eget kapital.

Avkastning på tillgångar

Avkastning på sysselsatt kapital

Upptäck starka bolag som tidigare presterat bra

7D

1Y

7D

1Y

7D

1Y

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2026/04/30 18:24
Aktiekurs vid dagens slut2026/04/30 00:00
Intäkter2025/12/31
Årlig intjäning2025/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Sutro Biopharma, Inc. bevakas av 17 analytiker. 11 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
Zhiqiang ShuBerenberg
Tazeen AhmadBofA Global Research
Thomas ShraderBTIG